At Wayne State University, a team of researchers has received $5.7 million to sit with one of medicine's quiet contradictions: body weight, long assumed to be the primary arbiter of metabolic health, does not tell the whole story of who develops insulin resistance and who does not. Over five years, they will look inside skeletal muscle at the molecular level, tracing the chemical modifications on proteins that may determine why some lean people lose insulin sensitivity while some living with obesity retain it. The work is both a scientific inquiry and a gesture of care toward the Detroit commu
NIH awards $5.7M to study why lean people develop insulin resistance
Body weight alone does not determine insulin sensitivity
Mark
Why does it matter that some lean people get insulin resistance? Isn't that rare?
Mimi
It's actually more common than people think, and it matters because it breaks the assumption that weight is destiny. If we only looked at body weight, we'd miss the real biology.
Luke
Do we know how common it is? The source doesn't give prevalence numbers.
Mimi
That's fair. But the point is that it exists, and when it does, it's dangerous—these lean people have the metabolic risk without the visible warning sign.
Mark
So the researchers are trying to find what's different about their muscle cells?
Mimi
Exactly. They're looking at chemical modifications on proteins—phosphorylation and O-GlcNAc glycosylation—to see which ones correlate with insulin resistance regardless of body weight.
Luke
And they're comparing four groups to isolate those differences. That's a solid design. But the database they're creating—will it actually lead to treatments, or is it just a resource?
Mimi
It's both. The database is the foundation. But they're also already looking at whether existing drugs could be repurposed based on what they find.
Mark
What's the timeline?
Mimi
Five years for the research. Then additional clinical trials would be needed before anything reaches patients.
Luke
So we're looking at a decade or more before we'd know if any of this translates to actual therapy.
Mimi
Yes. This is foundational science. It's not a cure announcement.
Mark
But it could change how we think about diabetes risk?
Mimi
That's the hope. If we can identify who's at risk before they show traditional signs, we could intervene earlier.
El Pulso
- The assumption that thinness protects against insulin resistance has quietly failed millions of people whose metabolic health diverges from what their body weight would predict.
- Researchers will compare four distinct groups — lean and obese, insulin-sensitive and insulin-resistant — to isolate the molecular signatures of resistance itself, stripped of the confounding variable of weight.
- The study's focus on protein modifications called phosphorylation and O-GlcNAc glycosylation targets the cellular 'switches' that govern how muscle tissue responds to insulin, a level of precision rarely attempted at this scale.
- A comprehensive, publicly shared database of these protein changes could accelerate the broader scientific community's understanding of metabolic disease well beyond this single study.
- Early findings may open a path toward repurposing existing FDA-approved drugs or developing new therapies targeting the enzyme OGT, though clinical trials remain a necessary horizon before patients could benefit.
At Wayne State University, a team of researchers has received $5.7 million to sit with one of medicine's quiet contradictions: body weight, long assumed to be the primary arbiter of metabolic health, does not tell the whole story of who develops insulin resistance and who does not. Over five years, they will look inside skeletal muscle at the molecular level, tracing the chemical modifications on proteins that may determine why some lean people lose insulin sensitivity while some living with obesity retain it. The work is both a scientific inquiry and a gesture of care toward the Detroit community, where the weight of type 2 diabetes is felt most acutely.
Wayne State University has secured a $5.7 million federal grant to investigate why insulin resistance does not follow the rules most people assume it does. Led by Dr. Zhengping Yi and Dr. Charlie Fehl, alongside colleagues from the School of Medicine, the five-year project asks a deceptively simple question: if body weight alone does not determine who develops insulin resistance, what does?
Insulin resistance — the condition in which cells stop responding effectively to the hormone that moves glucose into tissues — is a precursor to type 2 diabetes. But its relationship to obesity is far from absolute. Some lean individuals develop it; some people living with obesity never do. The research team will recruit Detroit-area volunteers and study skeletal muscle tissue from four groups that span this paradox, comparing the lean and the obese, the insulin-sensitive and the insulin-resistant, to find what biology actually separates these metabolic fates.
Their lens will be molecular: specifically, two types of chemical modifications that act as switches on proteins — phosphorylation and O-GlcNAc glycosylation. By mapping these modifications across thousands of proteins in muscle tissue, the team hopes to identify the pathways that distinguish healthy insulin response from resistance, independent of a person's weight. The resulting database will be shared openly with the scientific community, potentially accelerating research across the field of metabolic disease.
The findings may also carry practical consequences. The researchers will explore whether existing FDA-approved kinase inhibitors could be repurposed, or whether inhibiting an enzyme called OGT might offer a new therapeutic route — though clinical trials would be required before any such approach reaches patients. The project draws on the complementary expertise of Yi, who specializes in insulin signaling and proteomics, and Fehl, whose work focuses on tracking O-GlcNAc modifications in high-blood-sugar conditions. Together, they represent an interdisciplinary effort aimed not only at scientific discovery, but at addressing a disease that bears heavily on the community surrounding their university.
Wayne State University researchers have received a $5.7 million grant to investigate one of metabolism's persistent puzzles: why some people who are lean still develop insulin resistance, while some people living with obesity maintain healthy insulin sensitivity. The five-year project, funded by the National Institute of Diabetes and Digestive and Kidney Diseases, will examine the molecular machinery inside skeletal muscle to find the biological explanations for these divergent metabolic paths.
The research team is led by Dr. Zhengping Yi, a professor of pharmaceutical sciences, and Dr. Charlie Fehl, an associate professor of chemistry, along with co-investigators Dr. Berhane Seyoum and Dr. Seongho Kim from the School of Medicine. Their work centers on a fundamental question in diabetes prevention: if body weight alone does not determine insulin sensitivity, what does? Insulin is the hormone that allows cells to absorb glucose from the bloodstream and convert it to energy. When cells stop responding effectively to insulin—a condition called insulin resistance—blood sugar accumulates, and over time, type 2 diabetes can develop. Understanding the cellular mechanisms that drive this resistance independent of body weight could open new avenues for preventing the disease in at-risk populations.
The team will recruit volunteers from the Detroit area and study skeletal muscle tissue from four distinct groups: lean people with normal insulin sensitivity, lean people with insulin resistance, people with obesity who remain insulin sensitive, and people with obesity who have developed insulin resistance. By comparing these groups, the researchers can isolate the molecular differences that correlate with insulin resistance itself, separate from the effects of body weight. This design is crucial because it allows them to see what distinguishes a metabolically healthy lean person from a metabolically compromised one, and what allows some people with obesity to maintain insulin sensitivity.
The researchers will focus on two specific types of chemical modifications that occur on proteins: phosphorylation and O-GlcNAc glycosylation. These modifications act like switches and dials on cellular machinery, determining how proteins function and communicate with one another. By mapping these modifications across thousands of proteins in muscle tissue from all four groups, the team aims to identify the biological pathways that separate insulin-sensitive muscle from insulin-resistant muscle. The scale of this work is significant—they plan to create a comprehensive database of these protein modifications that will be made available to the broader research community, potentially accelerating discoveries in insulin resistance, obesity, and metabolic disease.
The findings may also point toward existing treatments. The researchers will investigate whether their discoveries could support repurposing FDA-approved kinase inhibitor drugs or provide justification for studying inhibitors that target an enzyme called OGT as a potential therapeutic approach to insulin resistance and type 2 diabetes. However, the team emphasizes that additional research, including clinical trials, would be necessary before any of these approaches could be tested in patients.
Dr. Yi, who joined Wayne State in 2011, brings expertise in insulin signaling, proteomics, and the large-scale study of proteins. His work integrates clinical, biological, biochemical, and computational approaches. Dr. Fehl, who arrived at Wayne State in 2018, specializes in understanding how O-GlcNAc glycosylation levels change in high-blood-sugar versus normal-blood-sugar conditions, and his group develops chemical tools to track and potentially treat these modifications in diabetes. Together, they represent the kind of interdisciplinary collaboration that the university's leadership sees as essential to advancing metabolic disease research. The project is positioned not only to generate new scientific knowledge but to do so in service of the local Detroit community, where the volunteers will be recruited and where the health burden of type 2 diabetes remains significant.
Citas Notables
This project is an excellent example of the important work our researchers are conducting that aims to impact the health and well-being of our local community and beyond.— Dr. Ezemenari M. Obasi, vice president for research & innovation at Wayne State University
By bringing together expertise from across Wayne State to better understand the complex biology of insulin resistance, this project has the potential to advance our knowledge to guide future approaches to preventing and treating type 2 diabetes.— Dr. Christine Rabinak, associate dean for research for WSU Applebaum
Quieres la nota completa?
Lee el original en news-medical.net ↗